Company Overview and News

1
Best Drill Interceptions In The Metals Mining Sector For The Week Ended 9 September 2018

2018-09-14 seekingalpha
Welcome to the fourth edition of Gold Panda's weekly series of articles covering the best drill interception in the metals mining sector. My first three articles from the series can be read here, here and here.
WLBMF AZZVF AVZ TECK

4
Lithium Junior Miner News For The Month Of August 2018

2018-08-27 seekingalpha - 1
Lithium market news - China’s lithium price decline is not the full picture to an industry surging.
LIT CXO SAV LAXXF LIACF AGY PFFOF WML POR ABEPF SQM MLNLF AVLNF AIS.H KDR SYA STLHF WMLLF LNRDY ADV ABE NGZ LMMFF GXY LRS PLU MNIKF HNR AMLM AVL ALB DMNXF MALRY MIN ARYMF LKE DDXFF MGXMF PLUUF DJIFF PSC EMH CRECF ERPNF PLS GSC NNO LTMCF DJI PDDTF NTTHF NNOMF AVLIF MALRF ORE AVZ AJM

 
Reshuffle in third week of Shares Race

2018-08-24 smh.com.au
Hina Chowdhary has retained first place in the third week of the Shares Race, but there’s been a reshuffle in the fortunes of other players.
KGI KGI.DB.A ZEE KGI.DB KL AVZ CANIF

 
AVZ establishes Manono as world’s largest hard rock spodumene deposit

2018-08-02 australianmining.com.au
AVZ Minerals has released a maiden mineral resource for the Manono project in the Democratic Republic of Congo (DRC), establishing the site as a major site for lithium production.
AVZ

4
Lithium Junior Miner News For The Month Of July 2018

2018-07-26 seekingalpha - 1
Lithium spot and contract price news - China spot prices slightly down in July, global contract prices remain strong.
LIT CXO SAV LAXXF LIACF PFFOF WML POR ABEPF SQM MLNLF AVLNF AIS.H SYA STLHF WMLLF LNRDY ABE NGZ LMMFF GXY LRS PLU MNIKF HNR AMLM AVL ALB DMNXF MALRY MIN LKE DDXFF MGXMF PLUUF DJIFF PSC EMH CRECF ERPNF PLS GSC NNO LTMCF DJI PDDTF NTTHF NNOMF AVLIF BCLMF MALRF ORE AVZ AJM

1
Lithium Miners News For The Month Of July 2018

2018-07-25 seekingalpha
Lithium market - Goldman: Concerns about a wave of supply of the electric car battery material from new mines are unfounded. The selloff in companies tied to lithium is overdone.
LIT BCN PILBF LTHHF CXO SAV LAXXF LIACF AGY NMT KSN PLLLY RDRUY AZZVF WML MLNLF AIS.H KDR DFS SYA STLHF WMLLF LNRDY NGZ LMMFF GXY TAW LRS MNIKF ILHMF AMLM DMNXF MALRY BGS LACDF EEYMF MIN NMKEF ARYMF ILC GALXF MGXMF LSSCF ALTAF DJIFF NMX EMH PSC CRECF OROCF ERPNF LAC PLS FTI.WI FMC BCN TWNAF DJI RRSSF PDDTF NTTHF AVLIF MALRF ORE AVZ AJM BCRMF

 
Hipo Resources completes Kamola lithium project due diligence, receives positive assays

2018-07-13 proactiveinvestors.com.au
Hipo Resources Ltd (ASX:HIP) has successfully completed technical and legal due diligence at its Kamola lithium project in the Democratic Republic of Congo (DRC) and will move forward with a 60% farm-in to the project.
CWMZF CWM AVZ

 
Flinders, AVZ in ASX clarifications

2018-06-29 businessnews.com.au
Two local mining companies have been forced to provide clarifications to the ASX this morning, with Flinders Mines responding to a leaked presentation from BBI Group, while lithium-focused AVZ Minerals told investors to ignore a Twitter post from one of its strategic advisers.
FLNDF FMS AVZ

 
AVZ Minerals drills record 341.62 metre lithium pegmatite intersection in DRC

2018-06-28 proactiveinvestors.com.au
AVZ Minerals Ltd (ASX:AVZ) has recorded the largest lithium pegmatite intersection to date from its Manono Lithium Project in the Democratic Republic of Congo.
AVZ

 
AVZ Minerals drills record 341m intersection at Manono project

2018-06-28 australianmining.com.au
AVZ Minerals has achieved a record 341.62m intersection from the Manono lithium project in the Democratic Republic of Congo (DRC).
AVZ

51
Lithium Junior Miner News For The Month Of June 2018

2018-06-27 seekingalpha - 1
Lithium market news: Joe Lowry significantly raised his new lithium demand forecast to ~800K MT LCE in 2025. Indian State-owned firms mandated to acquire overseas lithium and cobalt.
NI LIT CXO SAV LAXXF LIACF CYDVF AGY PFFOF WML POR ABEPF SQM MLNLF AVLNF AIS.H KDR SYA STLHF WMLLF LNRDY HMGLF PEMIF ABE NGZ LMMFF GXY LRS MNIKF PLU HNR AMLM 9984 AVL ALB DMNXF MALRY EEYMF SFTBF MIN NMKEF ARYMF LKE DDXFF MGXMF PLUUF DJIFF NMX PSC EMH CRECF ERPNF SFTBY PLS NNO DJI PDDTF NTTHF NNOMF CYP MALRF ORE AVZ AJM

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

19h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...